Yotam Nisemblat, MSc, MBA

Yotam Nisemblat is the Chief Scientific Officer and Co-Founder of X-tosis Inc., leading the development of novel VDAC1 oligomerization inhibitors as disease-modifying therapies for Parkinson’s disease. With over 19 years of experience in CNS drug development, he has overseen multiple preclinical and translational programs spanning discovery, pharmacology, and early clinical development. Previously, he served as CEO of ProteKt Therapeutics, advancing PKR inhibitors for neurodegenerative diseases, and as Drug Development Director at BioLineRx, where he led, among other programs, Parkinson’s research published in Neuroscience (2011). Nisemblat’s expertise covers target validation, biomarker development, and preclinical-to-clinical translation in neurodegenerative models. He holds an M.Sc. in Neurobiology from Tel Aviv University, a B.Sc. in Biotechnology and Food Engineering from the Technion, and an MBA in Finance and Risk Management from Reichman University. His work integrates scientific innovation with strategic development to advance novel therapies for Parkinson’s and other CNS disorders.